IQVIA Oncology Evidence Network (OEN)

The network to accelerate evidence generation

Access a network of European cancer hospitals and registries, and leverage the deep clinical expertise of IQVIA, to perform complex real world oncology studies.

Delivering high-quality real-world clinical evidence in oncology since 2016

Growing network of
35+

SITES across Europe

More than
60+

STUDIES delivered or ongoing

Studies commissioned by
20+

SPONSORS including large pharma companies and EBP

More than
60+

Publications generated

Access an established network of granular clinical data sources in Europe and beyond

Hybrid solution tailored to your evidence needs

Data is extracted directly from the clinical records, with EMR-structured information available being augmented with unstructured notes created during the patient journey in the OEN site. Any data generated during the patient journey can be leveraged to power retrospective, non-interventional and protocolised studies.

Expedite access to patient-level data

  • Accelerated feasibility process enabled by in-depth knowledge of site
  • On average, contracting an OEN site can be up to 5x faster than a non-OEN one
  • Sites can provide patient level data to conduct direct comparisons

Geared for precision oncology studies

  • 20+ biobanks and 15+ testing labs enabling retrospective biopsy testing
  • Generation of evidence for non-standard of care biomarkers
  • Access to specialized sites in Cell and Gene Therapies with minimal-to-no data lag

Leverage industry-leading capabilities

  • Large multi-disciplinary team in the RWE industry
  • End-to-end support, from evidence generation to submission to regulatory and HTA institutions
  • Involvement of treating physicians and data managers from sites

Making an impact across the entire product lifecycle

Our methodology and relationship with sites ensure the most comprehensive dataset are generated to meet evidence needs for all audiences. From internal stakeholders to HCPs, to regulatory or market access agencies, across the whole lifecycle of a product.

Leveraging real world data to develop robust scientific evidence
Understand current practices and evolution of the clinical standard of care by assessing treatment patterns and outcomes

Natural history of diseases studies provides essential insights into disease progression, patient populations, and long-term outcomes. These insights can be used for dissemination to the scientific community, to inform clinical trial design and to complement regulatory and market access submissions.


Selected case studies

Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe   Real-world analysis of epithelial ovarian cancer treatment and outcomes   Treatment patterns and outcomes in lenalidomide-exposed multiple myeloma patients   Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer
Contextualise results of single-arm trials against real world standard of care to support regulatory or HTA dossiers

External comparators enable to benchmark the effectiveness of a new treatment against existing therapies, either to fulfil regulatory requirements, market access and reimbursement decisions, or to support decision-making by investors. They can provide essential data on real-world effectiveness and safety, helping to identify patient populations and understand long-term outcomes.


Selected case studies

Outcomes in patients with relapsed/refractory DLBCL treated with systemic therapy   Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma   Efficacy comparison with standard of care in adults with advanced NSCLC with activating EGFR exon20ins   Comparison of idecabtagene vicleucel with real world outcomes in relapsed and refractory multiple myeloma
Generate comprehensive and longitudinal real-world evidence across over several markets and/or indications to serve multiple evidence purposes

Evidence Platforms leverage a network of sites to provide deep and longitudinal insights into clinical practices and outcomes. They can address wide evidence needs, from strategy planning to scientific dissemination, and be used to provide competitive advantage, enhance stakeholder engagement or guide product development and marketing activities.


Selected publications from the I-O Optimise Evidence Platform:

Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer   Real-world outcomes in patients with resected non-small cell lung cancer receiving (neo)adjuvant treatment in Germany   Treatment patterns and survival outcomes for advanced non-small cell lung cancer in the preimmunotherapy era in Portugal   Real-world outcomes in nonmetastatic non-small cell lung cancer
Access OEN biobanks to retrospectively test archived samples for non-standard of care biomarkers and identify target patients

Testing archived samples collected during the patient care journey for retrospective biomarker identification can be highly valuable for understanding outcomes and treatment patterns of biomarker-defined populations when investigating a new biomarker or a new mutational variant.


Selected case studies

Leveraging real world evidence to support oncology targeted therapies   Treatment patterns in ESR1 mutated patients with metastatic breast cancer
Evaluate the economic impact of treatments and interventions

HEOR studies evaluate the cost-effectiveness and real-world performance of new therapies. The results of these studies can be used to support reimbursement and pricing discussions.

Speak to us to find out how we can support your HTA dossier submission through a HEOR study

Get in touch to discuss your evidence needs
Speak to one of our experts how you can enhance your clinical development and ensure a successful drug launch by using robust scientific evidence
Contact Us